

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**NATL BREAST CANCER COALITION**

2. Address:

1707 L ST NW #1060, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: JENNIFER KATZ

Telephone: 202-973-0595

E-mail (optional): jkatz@natlbcc.org

Senate ID #: 52652-12

House ID #: 34898000

7. Client Name:  Self

### TYPE OF REPORT

8. Year 2001 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 88,900.00

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NATL BREAST CANCER COALITION Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

PRIORITY #1 \$175 million appropriation for the Department of Defense (DoD) peer-reviewed Breast Cancer Research Program (BCRP) for fiscal year (FY) 2003. PRIORITY #2 Enactment of H.R. 1624/S. 913, the Access to Cancer Therapies Act. The National Breast Cancer Coalition believes that Congress should enact comprehensive prescription drug coverage for Medicare beneficiaries. While NBCC supports a broad approach to prescription drug coverage, it believes that a special provision might be necessary for coverage of oral anti-cancer drugs in light of certain historical and cost considerations that argue for continued access to cancer therapy under Medicare Part B. This legislation will build on current Medicare policy by extending coverage to all cancer drugs, whether oral or injectable, for Medicare beneficiaries under Part B. PRIORITY #3 Enactment of S. 830/H.R. 1723, the Breast Cancer and Environmental Research Act. It is generally believed that the environment plays a role in the development of breast cancer, but the extent of that role is not understood. The National Breast Cancer Coalition believes that this critical issue must be approached thoughtfully and methodically and that a national strategy for increasing knowledge in this area must be developed. This legislation would make grants for multi-institutional, multi-disciplinary research centers to study the potential links between the environment and breast cancer. These centers would award grants based on a competitive, peer-reviewed process that involves consumer advocates. PRIORITY #4 Enactment of H.R. 602/S. 318, the Genetic Information Nondiscrimination in Health Insurance and Employment Act. The Kassebaum-Kennedy Health Insurance Reform Act (1996) took an important first step by including genetic information among the factors that may not be used to deny or limit insurance coverage for members in a group plan. Congress must now close the loopholes and provide comprehensive protection against genetic discrimination for all Americans. This legislation, which has strong enforcement mechanisms that include a right to sue, would prohibit health insurers and employers from discriminating based on genetic information. PRIORITY #5 Enactment of H.R. 2563/S. 1052, the Bipartisan Patient Protection Act. Patients deserve a comprehensive and enforceable patients' bill of rights, with a right to sue, that includes coverage for routine health care costs associated with clinical trials; access to the right providers; involvement in treatment decisions that are based on good science; confidentiality of their health information, and the right to receive accurate information about their health plans. These rights must be backed by strong enforcement mechanisms that include a private right of action in state court.

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ARENDS, WENDY  
Covered Official Position (if applicable): N/A  
Name: KATZ, JENNIFER  
Covered Official Position (if applicable): N/A  
Name: VISCO, FRANCES M.  
Covered Official Position (if applicable): N/A  
Name: WEXLER, ALANA  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Feb 14, 2002

Printed Name and Title: ALANA WEXLER - LEGISLATIVE AND POLICY ASSOCIATE